Read our latest publications
The 38th biannual report
This report was initiated by NHMRC’s Health Translation Advisory Committee. It contains the results of three connected research projects conducted between 2018 and 2019 which NHMRC commissioned to better understand the career pathways of clinician researchers.
Report on qualitative research about career pathways for Aboriginal and Torres Strait Islander clinician researchers
Clinician researchers are health professionals engaged in both patient care and research.
As such, they are uniquely placed to provide insights into their clinical practice and research, implementing evidence-based, best practice for their patients, and addressing clinically relevant problems through research.
The Health Translation Advisory Committee (HTAC) and the National Health and Medical Research Council (NHMRC) have previously explored concerns related to clinician researcher career pathways through a research project undertaken by ORIMA Research in 20191; however only 1% of research respondents identified as Aboriginal or Torres Strait Islander. As such, the NHMRC’s Principal Committee Indigenous Caucus (PCIC) and HTAC identified the need to undertake a project specifically with Aboriginal and Torres Strait Islander clinician researchers, to better understand their specific career experiences, enablers and barriers, as well as supports required to attract and retain this audience as clinician researchers.
Clinicians who combine clinical practice with research are an increasingly important,
but poorly understood, strategic resource for the translation of research into practice. There is limited information available about the career pathways of clinician researchers, and the reasons why some clinicians leave or choose not to enter research.
The Investigating Clinician Researcher Career Pathways Project (the project) was initiated as a priority project by National Health and Medical Research Council (NHMRC) Health Translation Advisory Committee (HTAC) during its 2015–2018 triennium. HTAC is a principal committee of NHMRC and provides advice to the CEO and Council of NHMRC on opportunities to improve health outcomes in areas including clinical care, public, population and environmental health and prevention of illness through effective translation of research into health care and clinical practice. The results of the project will assist HTAC in making recommendations to the CEO on the training and career pathways for clinician researchers.
NHMRC APS Census Results 2021
This report contains information on NHMRC administration and performance, and a record of our activities for the reporting period 2020 - 2021.
The NHMRC Corporate Plan 2021–22 presents our national strategy for health and medical research aligned with our three strategic purposes of investment, translation and integrity. The plan includes updated strategic priorities and health priorities and outlines our planned key activities in 2021–22 and over the next four years. The plan also describes the operating context in which we work and our performance criteria and targets for the next four years.
The 37th biannual report
Aboriginal and Torres Strait Islander health evidence-practice policy gap reports
Ten of the Best NHMRC research projects - twelfth edition describes ten Australian health and medical research projects chosen from among the thousands of NHMRC funded medical research projects underway in Australia today.
The 36th biannual report
This page provides access to the full guidelines and the underlying evidence base.
A plain English summary and resources to help you apply the guidelines in daily life are available on our alcohol health advice page.
The guidelines provide health professionals, policy makers and the Australian community with evidence-based advice on the health effects of drinking alcohol. The guidelines aim to help individuals make informed decisions about drinking alcohol. The guidelines are also intended to form the evidence base for policy making and educational materials.
This report contains information on NHMRC administration and performance, and a record of our activities for the reporting period 2019 - 2020.
The NHMRC Corporate Plan 2020-21 covers the four years to 2023-24. In line with legislated requirements, it identifies major health issues likely to arise, how NHMRC will deal with these issues (including the continuing impact of COVID-19) and our strategy for health and medical research. It also details the key activities NHMRC will undertake to achieve our purposes, and the operating context in which we work, comprising: environment, capability, risk oversight and management, and organisations NHMRC cooperates with to achieve our purposes.
The 35th biannual report
Measuring up 2018 is a five-year bibliometric analysis of the scientific publication output of Australian health and medical research, focusing on research funded by the National Health and Medical Research Council (NHMRC).
This Report from NHMRC’s Research Quality Workshop on 30 July 2019 outlines key messages, activities and initiatives within the research sector, and potential opportunities for collaboration to ensure the conduct of high quality research. Outcomes from the workshop will inform NHMRC’s ongoing activities to ensure the highest quality in NHMRC-funded research.
NHMRC’s Policy on Recognition acknowledges the role of Partners who support NHMRC in health and medical research. It sets out a strategy to recognise current and potential NHMRC Partners and how Partners recognise NHMRC.
This report contains information on NHMRC administration and performance, and a record of our activities for the reporting period 2018 - 2019.
Reference number: NH181
ISSN Print: 2209-7090
ISSN Online: 2209-7104
Payment of participants in research: information for researchers, HRECs and other ethics review bodies
NHMRC has developed advice that is designed to provide information for researchers and reviewers of research to assist in decision-making about when payment of participants in research is ethically acceptable.
The fundamental framework for the ethical, humane and responsible care and use of animals for scientific purposes in Australia includes the application of the 3Rs – Replacement, Reduction and Refinement of animal use. This Information Paper provides information about the implementation of the 3Rs in Australia. For further information, please refer to the webpage about the 3Rs.
The NHMRC Corporate Plan 2019-20 covers the period 2019-20 to 2022-23. It identifies the major health issues for this period, how we will deal with these issues and a strategy for medical research and public health research, in line with the requirements of the NHMRC Act. It also describes NHMRC’s purposes, planned activities and performance measures for the period and addresses our capability, environment and risk oversight and management.
The 34th biannual report
This report advises the NHMRC Chief Executive Officer on the current needs for research and clinical guidance for ME/CFS in Australia.
The guidelines are produced by the National Health and Medical Research Council in collaboration with the Australian Commission on Safety and Quality in Healthcare, and are published on the MAGICapp platform.
Ensuring the highest quality and value of NHMRC-funded research is a priority for NHMRC. NHMRC’s Research Quality Strategy outlines the key areas NHMRC will focus on to provide guidance and support for good research practices throughout the research cycle.
The 32nd biannual report.
The aim of NHMRC's Gender Equality Strategy is to achieve a gender-equal health and medical research workforce by supporting an increase in the retention and progression of women.
In conjunction with the Australian Clinical Trials Alliance, we developed the clinical trials competencies to be used in the development of detailed curricula and training courses by universities, Colleges and other registered training organisations*.
To improve clinical trial start-up times, we developed the Good Practice Process for Site Assessment and Authorisation Phases of Clinical Trial Research Governance (the Good Practice Process).
This annual report contains information on NHMRC administration and performance, and a record of our activities for the reporting period 2017–18.
Ten of the Best NHMRC Research Projects 2016 describes ten Australian health and medical research projects chosen from among the thousands of NHMRC funded medical research projects underway in Australia today.
The NHMRC Corporate Plan 2018–2019 covers the period 2018–19 to 2021–22. It identifies the major health issues for this period, how we will deal with these issues and a strategy for medical research and public health research, in line with the requirements of the NHMRC Act. It also describes NHMRC’s purposes, planned activities and performance measures for the period and addresses our capability, environment and risk oversight and management.
The National Statement on Ethical Conduct in Human Research (2007) (National Statement (2007), and as updated, consists of a series of guidelines made in accordance with the National Health and Medical Research Council Act 1992.
The 31st biannual report.
The Australian Code for the Responsible Conduct of Research, 2018 (the 2018 Code) establishes a framework for responsible research conduct that provides a foundation for high-quality research, credibility and community trust in the research endeavour.
Road Map 3: A strategic framework for improving Aboriginal and Torres Strait Islander health through research.
Linked to Action Plan 2018 - 2021 Triennium to implement Road Map 3 and Road Map 3: A strategic framework for improving Aboriginal and Torres Strait Islander health through research. Report of Community Consultation.
Road Map 3: A strategic framework for improving Aboriginal and Torres Strait Islander health through research. Report of Community Consultations.
A useful guide explaining key terms used in embryo research. Provides definitions of the main terms used, including biological definitions and therapy explanations.
This report contains information on our organisation, administration and performance for the reporting period 2016–17. It is a record of our activities during 2016–17 and the performance and financial information presented in the 2016–17 Portfolio (Agency) Budget Statement, 2016–17 Portfolio Additional Estimates Statement and the Corporate Plan 2016–2017.
This Kit is divided into five chapters, covering different aspects of the NHMRC Embryo Research Licensing Committee’s activities:
Managing individual exposure to lead in Australia – A guide for health practitioners (The Guide) provides health practitioners with general information to assist in the management of individuals with elevated blood lead levels.
This document provides advice on the conduct of animal-based studies to ensure that the studies are rigorous, transparent and reproducible and lead to useful outcomes. It is in line with the Australian Code for the care and use of animals for scientific purposes, 8th edition (2013), which is adopted into legislation across Australia.
This strategic plan outlines the major objectives of the NHMRC over the next three years, the major health issues that may emerge in the coming years and the steps needed to address them.
Based on a comprehensive review of the evidence and the translation of this evidence into the Information Paper Water fluoridation: dental and other human health outcomes, this also takes into consideration what the situation is here in Australia compared to elsewhere.
The 30th biannual report.
The NHMRC Corporate Plan 2017–2018 covers the period 2017–18 to 2020–21. It includes NHMRC’s strategic directions, which prior to 2015–16 were set out in the strategic plan.
This Information Paper explores the potential link between water fluoridation and human health based. The 2016 NHMRC Evidence Evaluation shows that water fluoridation helps to reduce tooth decay in children and adults. There is no reliable evidence that water fluoridation at current Australian levels causes health problems.